New drug displays anti-inflammatory and neuroprotective effects in ALS
NRG Therapeutics has shared preclinical and mechanistic data of its lead clinical asset NRG5051, a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson’s.
NRG disclosed that NRG5051, a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acts through a novel NLRX1-mediated mechanism of action.
The scientists at NRG and their collaborators at WEHI are among the first to demonstrate that NLRX1 is essential for mPTP opening, establishing it as a key component or regulator of pore function.
NLRX1 belongs to the NOD-like receptor family, a group of proteins that sense cellular stress and regulate immune responses. NLRX1 is unique within this family in being localised to the mitochondria.
The mPTP is a key inner mitochondrial membrane channel implicated in the toxic effects of misfolded TDP43, which accumulates in mitochondria and triggers energetic failure and a damaging interferon response.
Data presented confirmed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in acute NLS-TDP43 ALS mouse models, including reduced plasma neurofilament light (NfL) chain, a translatable fluid biomarker of neuronal damage.
Disease modifying ALS treatment
NRG5051 is currently in a Phase I clinical trial in healthy volunteers. Dosing in ALS patients is scheduled for later this year which will inform dose selection for future Phase II trials in ALS patients planned for 2027.
NRG Therapeutics’ Co-Founder and CEO Neil Miller said: “Alongside advancing NRG5051 through preclinical studies and now into human clinical trials, we are pleased to have unravelled its novel mode of action in modulating the mPTP. Prevention of mPTP opening, via NLRX1, restores mitochondrial integrity and protects the function of vulnerable neurons. NRG5051 has the potential to be a truly disease-modifying medicine, offering a major step forward in our goal to slow or prevent the progression of ALS and other neurodegenerative diseases.”
